For research use only. Not for therapeutic Use.
Inarigivir soproxil(Cat No.:I007292), also known as GS 9992 or SB 9200, is an oral agonist that targets innate immunity by activating the RIG-I and NOD2 pathways. This compound exhibits broad-spectrum antiviral activity against RNA viruses. It demonstrates an EC50 of 2.2 μM and 1.0 μM against Hepatitis C virus (HCV) genotypes 1a and 1b, respectively. By activating these immune pathways, inarigivir soproxil enhances the body’s natural antiviral defenses, making it a promising therapeutic option for the treatment of RNA viral infections, including HCV.
Catalog Number | I007292 |
CAS Number | 942123-43-5 |
Synonyms | Inarigivir soproxil; SB 44 (dinucleotide).;(((((2S,3S,5S)-5-(6-amino-9H-purin-9-yl)-3-hydroxytetrahydrofuran-2-yl)methoxy)(((2R,3R,4R,5R)-5-(2,4-dioxotetrahydropyrimidin-1(2H)-yl)-2-ethyl-4-methoxytetrahydrofuran-3-yl)oxy)phosphoryl)thio)methyl isopr |
Molecular Formula | C26H38N7O12PS |
Purity | ≥95% |
Target | HCV |
Solubility | Soluble in DMSO |
Storage | Store at -20°C |
IUPAC Name | [[(2R,3S,5R)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-2-(hydroxymethyl)-4-methoxyoxolan-3-yl]oxyphosphoryl]sulfanylmethyl propan-2-yl carbonate |
InChI | InChI=1S/C25H34N7O13PS/c1-12(2)42-25(37)40-11-47-46(38,45-19-14(7-33)44-23(20(19)39-3)31-5-4-16(35)30-24(31)36)41-8-15-13(34)6-17(43-15)32-10-29-18-21(26)27-9-28-22(18)32/h4-5,9-10,12-15,17,19-20,23,33-34H,6-8,11H2,1-3H3,(H2,26,27,28)(H,30,35,36)/t13-,14+,15+,17+,19+,20+,23+,46?/m0/s1 |
InChIKey | CJCYTUJOSMYXLE-JDLSZIHUSA-N |
SMILES | CC(C)OC(=O)OCSP(=O)(OCC1C(CC(O1)N2C=NC3=C(N=CN=C32)N)O)OC4C(OC(C4OC)N5C=CC(=O)NC5=O)CO |